Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage Study to Assess the Efficacy and Safety of 3 Doses of Crofelemer Orally Twice Daily for the Treatment of HIV-Associated Diarrhea
Latest Information Update: 04 Sep 2020
At a glance
- Drugs Crofelemer (Primary)
- Indications Diarrhoea
- Focus Registrational; Therapeutic Use
- Acronyms ADVENT
- Sponsors Salix Pharmaceuticals
- 25 Jul 2018 According to RedHill Biopharma media release, top-line results expected in the fourth quarter of 2018
- 24 Jul 2017 Results published in a Napo Pharmaceuticals media release.
- 24 Jul 2017 According to a Napo Pharmaceuticals media release, the results of a supplemental analysis were reported at the 9th International AIDS Society (IAS) Conference on HIV Science.